Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study
Authors
Keywords
-
Journal
JOURNAL OF AFFECTIVE DISORDERS
Volume 330, Issue -, Pages 7-15
Publisher
Elsevier BV
Online
2023-03-04
DOI
10.1016/j.jad.2023.02.151
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al.
- (2022) Guang Chen et al. MOLECULAR PSYCHIATRY
- Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability
- (2021) Jordi Bonaventura et al. MOLECULAR PSYCHIATRY
- Blinding and expectancy confounds in psychedelic randomized controlled trials
- (2021) Suresh D. Muthukumaraswamy et al. Expert Review of Clinical Pharmacology
- Magnitude of the Placebo Response Across Treatment Modalities Used for Treatment-Resistant Depression in Adults
- (2021) Brett D. M. Jones et al. JAMA Network Open
- Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis
- (2020) Anees Bahji et al. JOURNAL OF AFFECTIVE DISORDERS
- Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial
- (2019) Jennifer L. Phillips et al. AMERICAN JOURNAL OF PSYCHIATRY
- Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study
- (2019) Vanina Popova et al. AMERICAN JOURNAL OF PSYCHIATRY
- ( R )‐Ketamine exerts antidepressant actions partly via conversion to ( 2R,6R )‐hydroxynorketamine, while causing adverse effects at sub‐anaesthetic doses
- (2019) Panos Zanos et al. BRITISH JOURNAL OF PHARMACOLOGY
- Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)
- (2019) Maggie Fedgchin et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine
- (2019) Lijia Chang et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study
- (2018) Carla M. Canuso et al. AMERICAN JOURNAL OF PSYCHIATRY
- Finding factors that predict treatment-resistant depression: Results of a cohort study
- (2018) M. Soledad Cepeda et al. DEPRESSION AND ANXIETY
- (2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice
- (2018) Jun-ichi Yamaguchi et al. NEUROPSYCHOPHARMACOLOGY
- Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression
- (2018) Ella J. Daly et al. JAMA Psychiatry
- Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study
- (2018) A. Kautzky et al. ACTA PSYCHIATRICA SCANDINAVICA
- Antidepressant Potential of ( R )-Ketamine in Rodent Models: Comparison with ( S )-Ketamine
- (2017) Kenichi Fukumoto et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression
- (2016) Jaskaran B. Singh et al. AMERICAN JOURNAL OF PSYCHIATRY
- Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study
- (2016) Jaskaran B. Singh et al. BIOLOGICAL PSYCHIATRY
- NMDAR inhibition-independent antidepressant actions of ketamine metabolites
- (2016) Panos Zanos et al. NATURE
- Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine
- (2016) Chun Yang et al. PSYCHIATRY RESEARCH
- Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories
- (2016) T. Kishimoto et al. PSYCHOLOGICAL MEDICINE
- Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression
- (2016) Bangkun Yang et al. PSYCHOPHARMACOLOGY
- R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
- (2015) C Yang et al. Translational Psychiatry
- A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
- (2014) Kyle A.B. Lapidus et al. BIOLOGICAL PSYCHIATRY
- A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes
- (2014) A. McGirr et al. PSYCHOLOGICAL MEDICINE
- R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine
- (2013) Ji-chun Zhang et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started